RE:Pfizer March 19, 2024
- https://www.sandiegouniontribune.com/business/story/2024-03-19/pfizer-inks-large-deal-for-lab-space-at-new-torrey-view-campus-in-san-diego Pfizer Oncology has signed a 15-year, 230,000-square foot lease at the Torrey View life science campus nearing completion in San Diego by Breakthrough Properties, which is a joint venture between Tishman Speyer and biotechnology investment firm Bellco Capital.
The ten-acre campus is now fully pre-leased and the company claims that 89% of the three-building Torrey View is now secured by long-term investment grade credit (which is Pfizer), with the balance leased to biotechnology firms.
https://www.globest.com/2024/03/18/pfizer-takes-230k-sf-at-san-diego-life-science-campus/?slreturn=20240230105649
In addition Pfizer is conducting business at the following La Jolla location ..
"At our Global Research and Development site in La Jolla, California, a dedicated team of scientists is focused on discovering and developing potentially new groundbreaking therapies to treat many forms of cancer, including breast cancer — the most common invasive cancer worldwide, with over two million individuals impacted each year."
This has led to significant advancements in a new set of treatment options, called targeted therapies. Targeted therapies have the potential to treat specific types of breast cancer and can work in different ways, such as by activating the body’s immune system, killing cancer cells or stopping their replication, or overcoming their resistance to treatment. https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2021/story/spotlight-on-our-oncology-research-hub/
There are currently 4 general types of systemic therapy options for cancer treatment: chemotherapy, immunotherapy, endocrine therapy, and targeted therapy, with some overlap among the categories. For example, although immunotherapies are a form of targeted therapy, immunotherapy is a distinct class. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842142/